IPHA - Gunggung utang perusahaan Innate Pharma

The current price chart for Innate Pharma S.A. (IPHA) reflects the dynamics of separate debt, which stands at 0.00. The business focuses on developing agents to stimulate the body's defense against tumors. High barriers to entry are driven by strict FDA oversight and patent protection. The technology stack relies on artificial intelligence for molecular design, although final trials require direct medical supervision.

For Innate Pharma S.A. (IPHA), whose stability depends on licensing contracts with industry behemoths, the aggregate creditor burden on GURU.Markets reflects the level of external obligations. This indicator sums short-term and long-term borrowings to measure the business's financial leverage. The dynamics of liabilities illustrate debt service costs and the remaining liquidity available for development. Debt control is critical when navigating clinical phases, which defines the security's status as a high-risk asset.